reports
- Jonathan Moreland
ZBRA ZEBRA TECHNOLOGIES CORPORATION CLASS A
XRAY DENTSPLY SIRONA INC.
VNO VORNADO REALTY TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
FFIN FIRST FINANCIAL BANKSHARES INC
WD WALKER & DUNLOP INC.
AUP AURINIA PHARMACEUTICALS INC.
SABR SABRE CORP.
TREX TREX COMPANY INC.
AJG ARTHUR J. GALLAGHER & CO.
KKR KKR & CO. INC.
SMCI SUPER MICRO COMPUTER
AHCO INC.
DCTH ADAPTHEALTH
TSLX DELCATH SYSTEMS
THRY SIXTH STREET SPECIALTY LENDING
EOSE INC.
AGL THRYV HOLDINGS
FRSH EOS ENERGY ENTERPRISES INC (A)
FA AGILON HEALTH
CMTG INC.
MYN FRESHWORKS INC.
WRB FIRST ADVANTAGE CORP NEW
BLCO CLAROS MORTGAGE TRUST
NMTC INC.
MSDL BLACKROCK MUNIYELD N Y INSD FD INC
LAW W.R. BERKLEY CORPORATION
BAUSCH + LOMB CORP
NEUROONE MEDICAL TECHNOLOGIES CORP
MORGAN STANLEY DIRECT LENDING
CS DISCO INC
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financi...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results – ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted ...
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual He...
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed or by visiting Madrigal’s Investor Relations Events . A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopha...
Arq Schedules Fourth Quarter & Full-Year 2025 Earnings Conference Call
Arq Schedules Fourth Quarter & Full-Year 2025 Earnings Conference Call GREENWOOD VILLAGE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- GlobeNewswire - Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced the Company will release its fourth quarter and full-year 2025 financial results after market close on Monday, March 9, 2026. A conference call to discuss the Company's financial performance is scheduled for Tuesday, March 10, 2026 at 8:30 a.m. Eas...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ACN ACCENTURE PLC CLASS A
WK WORKIVA
WDAY WORKDAY INC. CLASS A
THRM GENTHERM INCORPORATED
SXT SENSIENT TECHNOLOGIES CORPORATION
SFM SPROUTS FARMERS MARKETS INC.
NSP INSPERITY INC.
HTGC HERCULES CAPITAL INC.
GPC GENUINE PARTS COMPANY
FELE FRANKLIN ELECTRIC CO. INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CRY CRYOLIFE INC.
CPRT COPART INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ATRC ATRICURE INC.
STN. STANTEC INC
TLX TALANX AG
FLTR FLUTTER ENTERTAINMENT PLC
BRO BROWN & BROWN INC.
SLM SLM CORP
TREE LENDINGTREE INC.
USLM U.S. LIME & MINERALS
WCN WASTE CONNECTIONS INC.
GIB.A CGI INC. CLASS A
CHWY CHEWY INC. CLASS A
QS QUANTUMSCAPE
SOFI SOFI TECHNOLOGIES INC
BWMN BOWMAN CONSULTING GROUP LTD
TPG TPG INC
SMR NUSCALE POWER CORP
ALAB ASTERA LABS INC
CAI CARIS LIFE SCIENCES INC
PTRN PATTERN GROUP INC.
LCID LUCID GROUP INC.
GDYN GRID DYNAMICS HOLDINGS INC.
APPE1 ASAN PARDAKHT PERSIAN ORD
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Fin...
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- M...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in...
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financi...
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following which will provide partic...
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agr...
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatmentMadrigal will develop next-generation siRNA therapies that silence genes implicated in MASH CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metaboli...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 1, 2026 to 21 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 ...
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Inv...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nas...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted an equity award on January 15, 2026 to Rita Thakkar, the company’s new Chief Accounting Officer, as an equity inducement award under the terms of Madrigal’s 2025 Inducement Plan. The equity award was approved by Madrigal’s Board of Dire...
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2...
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron. “In addition to our revenue ...
Madrigal Expands its MASH Pipeline with Exclusive Global License Agree...
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDG...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
NKE NIKE INC. CLASS B
ALT ALTIMMUNE INC
COO THE COOPER COMPANIES INC.
NUVL NUVALENT INC
MAIA MAIA BIOTECHNOLOGY INC
HYMC HYCROFT MINING HOLDING CORPORATION
RMI RIVERNORTH OPPOR MUN INC FD INC
MPTI M-TRON INDUSTRIES
INC.
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
IGR CBRE CLARION GLOBAL REAL ESTAT
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
AZYO AZIYO BIOLOGICS
DLHC DALEIGH HOLDINGS CORP
IMNM IMMUNOME
PROP PRAIRIE OPERATING CO.
MXF THE MEXICO FUND
GF INC.
HYMC THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
CLFD CLEARFIELD INC.
CDXS CODEXIS
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
DIS THE WALT DISNEY COMPANY
ELAN ELANCO ANIMAL HEALTH INC.
MIDD THE MIDDLEBY CORPORATION
AMCR AMCOR PLC
RZLT REZOLUTE
ZNTL INC.
BMEA ZENTALIS PHARMACEUTICALS
NRDY BIOMEA FUSION
KVUE INC.
PROP NERDY INC.
NEXT KENVUE INC
SPRU PRAIRIE OPERATING CO.
MXF NEXTSOURCE MATERIALS INC.
GF SPRUCE POWER HOLDING CORP
AFCG THE MEXICO FUND
SI INC.
SEVN THE NEW GERMANY FUND
INC.
AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
SEVEN HILLS REALTY TRUST
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Hea...
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST. The presentation will be broadcast live and can be accessed or by visiting Madrigal’s Investor Relations Events and Presentations . A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biophar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.